AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8784893 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraosseous injection with 1.8 ml of 2% lidocaine with 1:100,000 epinephrine
Number of subjects: 40
Study 8784893 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraosseous injection
Number of subjects: 40
Study 1461544 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine retard (40 mg twice a day)
Number of subjects: 174
Study 1461544 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (25 mg twice a day)
Number of subjects: 174
Study 1461544 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine retard + Hydrochlorothiazide (12.5 mg/day after 2 months if needed)
Number of subjects: 174
Study 1461544 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril + Hydrochlorothiazide (12.5 mg/day after 2 months if needed)
Number of subjects: 174
Study 1461544 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine retard
Number of subjects: 174
Study 1461544 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 174
Study 6597708 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine (40 mg, 2 ml of 2% lidocaine mixed with 50 ml of contrast medium)
Number of subjects: 60
Study 6597708 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 60
Study 6597708 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine and Saline (both groups)
Number of subjects: 60
Study 31502003 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinogen/Thrombin-Coated Collagen Patch (TachoSil®)
Number of subjects: 124
Study 31502003 — intervention group
Group type: COMPARATOR
Intervention: Control (no fibrin sealant patch)
Number of subjects: 124
Study 29661389 — intervention group
Group type: EXPERIMENTAL
Intervention: Esketamine (cumulative dose 40 mg infused in 1 h)
Number of subjects: 12
Study 29661389 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 29661389 — intervention group
Group type: COMPARATOR
Intervention: Remifentanil
Number of subjects: 12
Study 29187490 — intervention group
Group type: EXPERIMENTAL
Intervention: IMRT
Number of subjects: 30
Study 29187490 — intervention group
Group type: COMPARATOR
Intervention: RT
Number of subjects: 30
Study 26704011 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral 500 ml of 10% glucose solution two hours before surgery
Number of subjects: 35
Study 26704011 — intervention group
Group type: COMPARATOR
Intervention: Fasting for 8‐12 hours before operation (Control)
Number of subjects: 35
Study 26704011 — intervention group
Group type: COMPARATOR
Intervention: Trial group (Oral carbohydrate) vs Control group (Fasting)
Number of subjects: 35
Study 24088271 — intervention group
Group type: EXPERIMENTAL
Intervention: IgM-enriched intravenous immunoglobulin (IVIG)
Number of subjects: 38
Study 24088271 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 24088271 — intervention group
Group type: EXPERIMENTAL
Intervention: Both IVIG and placebo
Number of subjects: 38
Study 21438938 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone
Number of subjects: 3
Study 21438938 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 3
Study 18444869 — intervention group
Group type: EXPERIMENTAL
Intervention: Switch arm (half dose of stavudine)
Number of subjects: 24
Study 18444869 — intervention group
Group type: COMPARATOR
Intervention: Continuation arm (standard dose of stavudine)
Number of subjects: 24
Study 18444869 — intervention group
Group type: COMPARATOR
Intervention: Comparison between groups
Number of subjects: 24
Study 16522418 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure at the P6 point
Number of subjects: 80
Study 16522418 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 12657345 — intervention group
Group type: EXPERIMENTAL
Intervention: 1200 mg calcium supplement for 10 days
Number of subjects: 31
Study 12657345 — intervention group
Group type: COMPARATOR
Intervention: Multivitamin without calcium for 10 days
Number of subjects: 31
Study 10829467 — intervention group
Group type: EXPERIMENTAL
Intervention: Levothyroxine
Number of subjects: 0
Study 10829467 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9052302 — intervention group
Group type: COMPARATOR
Intervention: PCEA HM 3‐mL (0.15 mg) bolus doses + saline 1 mL IV q6h (Group 1)
Number of subjects: 62
Study 9052302 — intervention group
Group type: COMPARATOR
Intervention: PCEA HM (0.15 mg) in 0.125% bupivacaine 3‐mL bolus doses + saline 1 mL IV q6h (Group 2)
Number of subjects: 62
Study 9052302 — intervention group
Group type: EXPERIMENTAL
Intervention: PCEA HM 3‐mL (0.15 mg) bolus doses + ketorolac 1 mL (30 mg) IV q6h (Group 3)
Number of subjects: 62
Study 8379601 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (400 mg)
Number of subjects: 8
Study 3518381 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 37
Study 3518381 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 29676979 — intervention group
Group type: EXPERIMENTAL
Intervention: HP 10 (10% Hydrogen Peroxide)
Number of subjects: 78
Study 29676979 — intervention group
Group type: COMPARATOR
Intervention: HP 4 (4% Hydrogen Peroxide)
Number of subjects: 78
Study 29676979 — intervention group
Group type: EXPERIMENTAL
Intervention: Both HP 4 and HP 10
Number of subjects: 78
Study 27455158 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative chemical thromboprophylaxis (CTP) with 5000 units of subcutaneous heparin
Number of subjects: 376
Study 27455158 — intervention group
Group type: COMPARATOR
Intervention: Postoperative chemical thromboprophylaxis (CTP) with 5000 units of subcutaneous heparin
Number of subjects: 376
Study 25415813 — intervention group
Group type: EXPERIMENTAL
Intervention: PTNS plus tolterodine (4 mg daily for three months)
Number of subjects: 50
Study 25415813 — intervention group
Group type: COMPARATOR
Intervention: Tolterodine alone (4 mg daily for three months)
Number of subjects: 50
Study 23525434 — intervention group
Group type: EXPERIMENTAL
Intervention: Diesel exhaust inhalation
Number of subjects: 0
Study 23525434 — intervention group
Group type: COMPARATOR
Intervention: Filtered air
Number of subjects: 0
Study 20951978 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency bilateral subthalamic nucleus (STN) deep brain stimulation (DBS)
Number of subjects: 10
Study 20951978 — intervention group
Group type: COMPARATOR
Intervention: Off-Stimulation status
Number of subjects: 10
Study 20951978 — intervention group
Group type: EXPERIMENTAL
Intervention: On-Stimulation conditions
Number of subjects: 10
Study 19143244 — intervention group
Group type: EXPERIMENTAL
Intervention: Paper splint adduction fixation
Number of subjects: 70
Study 19143244 — intervention group
Group type: COMPARATOR
Intervention: Plaster abduction fixation
Number of subjects: 70
Study 16622748 — intervention group
Group type: EXPERIMENTAL
Intervention: JTE‐522 (tiracoxib) 150 mg once daily for 26 weeks
Number of subjects: 61
Study 16622748 — intervention group
Group type: EXPERIMENTAL
Intervention: JTE‐522 (tiracoxib) 200 mg once daily for 26 weeks
Number of subjects: 61
Study 16622748 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 16622748 — intervention group
Group type: EXPERIMENTAL
Intervention: JTE‐522 (tiracoxib) 150 mg and 200 mg
Number of subjects: 61
Study 12610786 — intervention group
Group type: EXPERIMENTAL
Intervention: Classroom interventions using Health Promotion/Transtheoretical Model
Number of subjects: 60
Study 12610786 — intervention group
Group type: COMPARATOR
Intervention: Usual classroom education (Control)
Number of subjects: 60
Study 11199241 — intervention group
Group type: EXPERIMENTAL
Intervention: One-hour educational intervention
Number of subjects: 137
Study 11199241 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (scheduled to receive the intervention later)
Number of subjects: 137
Study 8810935 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular human insulin 100 U mL‐1 (Actrapid) at a dose of 160 U
Number of subjects: 8
Study 8810935 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline (control)
Number of subjects: 8
Study 7917439 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation counseling during hospitalization; at least one of nine counseling procedures related to smoking cessation.
Number of subjects: 43
Study 7917439 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation counseling during hospitalization; more than one counseling procedure.
Number of subjects: 43
Study 7917439 — intervention group
Group type: EXPERIMENTAL
Intervention: Information about symptoms of nicotine withdrawal, means of abstaining during hospitalization, means of permanently quitting, or medications for nicotine withdrawal symptoms.
Number of subjects: 43
Study 7917439 — intervention group
Group type: EXPERIMENTAL
Intervention: Inclusion of smoking cessation in plans for future care upon hospital discharge.
Number of subjects: 43
Study 7917439 — intervention group
Group type: EXPERIMENTAL
Intervention: Attitude towards the hospital's nonsmoking policy.
Number of subjects: 43
Study 2969315 — intervention group
Group type: EXPERIMENTAL
Intervention: cilazapril (mean dose 3.6 +/- 0.9 mg/day)
Number of subjects: 18
Study 2969315 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 18
Study 31937274 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized individual and family‐based suicidal behaviour risk reduction intervention (SPS)
Number of subjects: 128
Study 31937274 — intervention group
Group type: COMPARATOR
Intervention: Case navigation (NAV)
Number of subjects: 128
Study 31185955 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised group exercise two days a week for one hour each (intervention B)
Number of subjects: 117
Study 31185955 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual physical exercise minimum two days a week (intervention C)
Number of subjects: 117
Study 31185955 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (control A)
Number of subjects: 117
Study 28320793 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg berryfruit polyphenolic extract (BFPE)
Number of subjects: 28
Study 28320793 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 28320793 — intervention group
Group type: COMPARATOR
Intervention: BFPE vs Placebo
Number of subjects: 28
Study 26156941 — intervention group
Group type: EXPERIMENTAL
Intervention: Workplace physical exercise (WORK) performed in groups during working hours for 5×10 minutes per week
Number of subjects: 200
Study 26156941 — intervention group
Group type: COMPARATOR
Intervention: Home-based physical exercise (HOME) performed during leisure time for 5×10 minutes per week
Number of subjects: 200
Study 24130356 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin detemir
Number of subjects: 28
Study 24130356 — intervention group
Group type: COMPARATOR
Intervention: NPH insulin
Number of subjects: 28
Study 21455974 — intervention group
Group type: EXPERIMENTAL
Intervention: Female participants
Number of subjects: 65
Study 21455974 — intervention group
Group type: COMPARATOR
Intervention: Male participants
Number of subjects: 65
Study 19583714 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal repair with mesh augmentation (mesh group, n = 69)
Number of subjects: 139
Study 19583714 — intervention group
Group type: COMPARATOR
Intervention: Traditional anterior and posterior colporrhaphy (no mesh group, n = 70)
Number of subjects: 139
Study 19583714 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (mesh and no mesh)
Number of subjects: 139
Study 19583714 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal repair with mesh augmentation (mesh group)
Number of subjects: 139
Study 19583714 — intervention group
Group type: COMPARATOR
Intervention: Traditional anterior and posterior colporrhaphy (no mesh group)
Number of subjects: 139
Study 17846310 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF (10 microg/kg/d)
Number of subjects: 78
Study 15535408 — intervention group
Group type: EXPERIMENTAL
Intervention: History of incarceration within 12 months of initiating HAART
Number of subjects: 1746
Study 15535408 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher adherence
Number of subjects: 1746
Study 15535408 — intervention group
Group type: EXPERIMENTAL
Intervention: Time spent in jail among incarcerated subjects
Number of subjects: 1746
Study 11820338 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice nurse-led coronary preventive care
Number of subjects: 0
Study 9516068 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive status measured by MMSE in patients with cardiovascular complications
Number of subjects: 3111
Study 9516068 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate alcohol consumption in women
Number of subjects: 3111
Study 9516068 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment of systolic hypertension with calcium antagonists
Number of subjects: 3111
Study 9516068 — intervention group
Group type: COMPARATOR
Intervention: Cognitive status measured by MMSE
Number of subjects: 3111
Study 7759428 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 degrees head-down tilt (HDT) for 10 hours
Number of subjects: 8
Study 1707109 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (DZ) pretreatment and infusion (0.12 mg/kg/h for 74 hours starting 2 hours prior to surgery, continued with 90 mg b.i.d. p.o. until day 30)
Number of subjects: 134
Study 1707109 — intervention group
Group type: COMPARATOR
Intervention: Control group (no diltiazem)
Number of subjects: 134
Study 290726 — intervention group
Group type: EXPERIMENTAL
Intervention: Propoxyphene napsylate (50, 100, and 150 mg)
Number of subjects: 0
Study 290726 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoprofen calcium (200, 400, and 600 mg)
Number of subjects: 0
Study 290726 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of propoxyphene (50/200, 100/400, and 150/600 mg)
Number of subjects: 0
Study 290726 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 290726 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (650 mg)
Number of subjects: 0
Study 31310960 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated amniotic fluid-like solution (SAFE)
Number of subjects: 40
Study 31310960 — intervention group
Group type: COMPARATOR
Intervention: Distilled water (placebo)
Number of subjects: 40
Study 28597355 — intervention group
Group type: EXPERIMENTAL
Intervention: Vesair intravesical balloon
Number of subjects: 75
Study 26306733 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified constraint-induced movement therapy protocol (180 min of treatment/day for 10 days)
Number of subjects: 24
Study 26306733 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified constraint-induced movement therapy protocol
Number of subjects: 24
Study 22899425 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment for managing dysfunctional thoughts about caregiving and training in self-help techniques
Number of subjects: 125
Study 22899425 — intervention group
Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 125
Study 21959255 — intervention group
Group type: EXPERIMENTAL
Intervention: Zotarolimus-eluting stents (ZES)
Number of subjects: 611
Study 21959255 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents (SES)
Number of subjects: 611
Study 21959255 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stents (PES)
Number of subjects: 611
Study 18219701 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 0
Study 16546755 — intervention group
Group type: EXPERIMENTAL
Intervention: Metallothionein-III (MT-III) gene polymorphisms
Number of subjects: 37
Study 16546755 — intervention group
Group type: EXPERIMENTAL
Intervention: Metallothionein-IIA (MT-IIA) promoter region SNPs
Number of subjects: 37
Study 16546755 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 37
Study 12678210 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflavone supplements
Number of subjects: 0
Study 10896637 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone
Number of subjects: 40
Study 10896637 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 2012777 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA cream
Number of subjects: 115
Study 2012777 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 115
Study 6758757 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure (behaviorally-focused method)
Number of subjects: 34
Study 6758757 — intervention group
Group type: EXPERIMENTAL
Intervention: Applied relaxation (physiologically-focused method)
Number of subjects: 34
Study 6758757 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 34
Study 31183382 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Karate (60 minutes twice a week for at least one year)
Number of subjects: 152
Study 31183382 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Karate
Number of subjects: 152
Study 29797529 — intervention group
Group type: EXPERIMENTAL
Intervention: NASH subjects
Number of subjects: 40
Study 29797529 — intervention group
Group type: EXPERIMENTAL
Intervention: Engaging in dedicated cardiovascular activity
Number of subjects: 40
Study 26946333 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver transplantation (LT)
Number of subjects: 32810
Study 26946333 — intervention group
Group type: EXPERIMENTAL
Intervention: Age >65 years
Number of subjects: 32810
Study 26946333 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcoholic cirrhosis
Number of subjects: 32810
Study 26946333 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonalcoholic steatohepatitis (NASH)
Number of subjects: 32810
Study 26946333 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre‐LT creatinine
Number of subjects: 32810
Study 26946333 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline atrial fibrillation (AF)
Number of subjects: 32810
Study 26946333 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke
Number of subjects: 32810
Study 26946333 — intervention group
Group type: EXPERIMENTAL
Intervention: MACE
Number of subjects: 32810
Study 24779562 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer duration of diabetes
Number of subjects: 614
Study 24779562 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher fasting plasma glucose level
Number of subjects: 614
Study 24779562 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemoglobin A1c level
Number of subjects: 614
Study 21684022 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapy intervention (PTI)
Number of subjects: 48
Study 21684022 — intervention group
Group type: COMPARATOR
Intervention: Control group (pre-frail elderly women)
Number of subjects: 48
Study 20801187 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month endurance training
Number of subjects: 0
Study 20801187 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month strength training
Number of subjects: 0
Study 20801187 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone treatment in orchiectomised rats
Number of subjects: 0
Study 20801187 — intervention group
Group type: EXPERIMENTAL
Intervention: Bodybuilders
Number of subjects: 0
Study 20801187 — intervention group
Group type: COMPARATOR
Intervention: Untrained volunteers
Number of subjects: 0
Study 20801187 — intervention group
Group type: COMPARATOR
Intervention: Tetraplegic patients
Number of subjects: 0
Study 17388762 — intervention group
Group type: EXPERIMENTAL
Intervention: Binaural beat at 7 Hz (30 minutes) with pink noise overlay
Number of subjects: 4
Study 17388762 — intervention group
Group type: COMPARATOR
Intervention: Control stimuli without binaural beat (30 minutes) with pink noise overlay
Number of subjects: 4
Study 16110692 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin 0.05 mg
Number of subjects: 20
Study 16110692 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin 0.10 mg
Number of subjects: 20
Study 16110692 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin 0.15 mg
Number of subjects: 20
Study 16110692 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin 0.20 mg
Number of subjects: 20
Study 16110692 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 12100776 — intervention group
Group type: EXPERIMENTAL
Intervention: Valdecoxib 10 mg once daily
Number of subjects: 0
Study 12100776 — intervention group
Group type: EXPERIMENTAL
Intervention: Valdecoxib 20 mg once daily
Number of subjects: 0
Study 12100776 — intervention group
Group type: EXPERIMENTAL
Intervention: Valdecoxib 5 mg once daily
Number of subjects: 0
Study 12100776 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen 500 mg twice daily
Number of subjects: 0
Study 12100776 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12100776 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen
Number of subjects: 0
Study 12100776 — intervention group
Group type: EXPERIMENTAL
Intervention: Valdecoxib 5 mg and 10 mg
Number of subjects: 0
Study 12100776 — intervention group
Group type: EXPERIMENTAL
Intervention: Valdecoxib 20 mg
Number of subjects: 0
Study 10410152 — intervention group
Group type: COMPARATOR
Intervention: Granisetron alone
Number of subjects: 27
Study 10410152 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron plus methylprednisolone
Number of subjects: 27
Study 7564369 — intervention group
Group type: EXPERIMENTAL
Intervention: moexipril 3.75 mg o.d.
Number of subjects: 203
Study 7564369 — intervention group
Group type: EXPERIMENTAL
Intervention: moexipril 7.5 mg o.d.
Number of subjects: 203
Study 7564369 — intervention group
Group type: EXPERIMENTAL
Intervention: moexipril 15 mg o.d.
Number of subjects: 203
Study 7564369 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 203
Study 2187173 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonatal screening using IRT cutoff of 180 ng/mL
Number of subjects: 145024
Study 6617280 — intervention group
Group type: EXPERIMENTAL
Intervention: heparin and hydrocortisone
Number of subjects: 100
Study 6617280 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 100
Study 31462121 — intervention group
Group type: EXPERIMENTAL
Intervention: 595 nm pulsed-dye-laser (PDL) treatment (3 treatments, 10 mm spot size, 0.45 ms, 6 J/cm2)
Number of subjects: 40
Study 31462121 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated half of the scar)
Number of subjects: 40
Study 29402509 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise Training (AER)
Number of subjects: 30